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Introduction: Inflammation might be an important underlying cause of preterm birth. Our aim is to 
explore whether vaginal administration α-lipoic acid reduces cervical inflammation and shortening 
after primary tocolysis. 
Matherials and Methods: Singleton pregnancies between 24-30 weeks remaining undelivered 
after hospitalization for preterm labor were randomly allocated to placebo (20 women, 15 analyzed) 
or vaginal ALA 400 mg daily (20 women, 17 analyzed) for 30 days. A cervical swab to quantify 
pro-inflammatory (IL1, IL2, IL6, IL8, TNFα) and anti-inflammatory (IL4, IL10) cytokines as well 
as transvaginal ultrasound cervical length measurement (CL) were performed before and after 
treatment.  
Results: The % changes of pro-inflammatory cytokines do not differ between treatment groups, 
while IL4 significantly increases by vaginal ALA in comparison to placebo (118.0±364.3% vs. 
29.9±103.5%, p=0.012). Combined anti-inflammatory cytokines show same trend (292.5±208.5% 
vs. 64.5±107.4, p=0.03). CL remains similar in vaginal ALA group (from 23.1±6.6 to 20.80±7.9 
mm), while it significantly decreased in placebo group (from 20.4±6.5 to 13.8±7.5 mm, p<0.001 vs. 
Baseline; p=0.003 vs. vaginal ALA).  
Conclusion: Vaginal ALA significantly stimulates anti-inflammatory ILs in the cervix of 
undelivered women after a preterm labor episode. This effect is associated with a stabilization of the 
CL. 
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The overall rate of preterm birth (PTB) is steadily increasing in the developed world [1,2]. Recent 
clinical and experimental evidence supports the syndromic nature of PTB [3] which derives from 
four pathogenic processes, sharing a common final biological pathway leading to uterine 
contractions and cervical changes with or without premature rupture of membranes: 1) the decidual-
chorioamniotic or systemic inflammation, 2) the decidual haemorrhage, 3) the activation of the 
maternal or fetal hypothalamic-pituitary-adrenal axis, 4) pathological distention of the uterus [4].   
Strategies to prevent preterm labor/PTB can now be taken into account in view of the availability of 
drugs and devices. Among them, treatment with progestogens to prevent PTB has represented the 
major research focus in the last years. Several studies have demonstrated the efficacy of either 
vaginal progesterone (P) or intramuscular 17α-hydroxyprogesterone caproate for the prevention of 
PTB in asymptomatic women with singleton pregnancy with a history of a previous preterm birth 
[5-7]. Moreover, evidence support the efficacy of vaginal P in asymptomatic women presenting 
with an objectively evaluated short cervix at mid pregnancy [8]. On the other hand, the efficacy of 
progestogens in women remaining undelivered after an episode of PTL remain to be demonstrated, 
as controversial data have been published [9-12].  For this reason new approaches to PTB 
prevention are needed [13], namely in the field of the so called “secondary or maintenance 
tocolysis”.   
Alpha-lipoic acid (ALA), also known as thioctic acid, and its reduced form, dihydrolipoic acid 
(DHLA), are naturally occurring compounds [14] with a well-known anti-oxidant and anti-
inflammatory profile [15], probably via the inhibition of nuclear factor κ beta (NF-κB) signaling 
pathway [16]. NF-κB plays a fundamental role in the expression of various genes involved in 
inflammatory response and in cell apoptosis processes and it has a central role in labor-associated 









and NF-κB activity mediates cyclo-oxygenase (COX)-2 expression in the human amnion during 
labor [17]. Its stimulation is connected to the cell’s exposure to lipopolysaccharide, inflammatory 
cytokines (tumor necrosis factor (TNF)-α and interleukin (IL)-1), lack of progesterone, growth 
factors, free radicals and many other physiological and nonphysiological stimuli [18]. It has been 
observed that treatment with ALA was effective both in inhibiting the degradation of the IκB, a 
protein that inhibits NF-κB, and in directly reducing the expression of NF-κB and of matrix 
metalloproteinase-9 (MMP-9), an enzyme responsible for the degradation of the extracellular matrix 
[19]. This enzyme has been associated to PTB as its increased levels in amniotic fluid and its 
enhanced gene expression in fetal membranes have been associated with preterm rupture of 
membranes compared with other causes of PTB and TNFα-induced MMP-9 expression results in a 
significant decrease in the force needed to rupture human term fetal membranes [20]. LA in vitro 
treatment inhibited TNFα-induced weakening of fetal membranes and cytokine-induced MMP9 and 
prostaglandins production in both intact fetal membranes and amnion cells suggesting that its 
supplementation during pregnancy might prove clinically useful in prevention of preterm premature 
rupture of fetal membranes [21]. Recently it was also shown by preliminary trials that ALA, 
administered by oral or vaginal route, is able to potentiate the effect of progesterone in the healing 
process of threatened miscarriage and it may speed up the process of subchorionic hematoma 
resorption, by enhancing the levels of Vascular Endothelial Growth Factor (VEGF) and alpha 
Smooth Muscle Actin (alpha-SMA) and decreasing the expression of NF-κB and MMP-9 [22, 23]. 
1.2 Rationale 
ALA, acting on different pathways involved in the pathogenesis of PTB [24], could be a molecule 
of interest. Thus, we have decided to investigate the vaginal administration of ALA looking at its 










2. Materials and Methods 
This was a pilot, prospective, randomized, placebo-controlled, parallel group, monocenter trial. The 
study was conducted from January 2015 to February 2016 in the Azienda Ospedaliero-Universitaria 
Policlinico of Modena in the Unit of Obstetrics and Gynaecology. The randomization allocation 
was 1:1 (vaginal ALA:placebo) and was accomplished using an electronic randomization list. 
2.1 Subjects 
A written informed consent was collected from all patients prior to inclusion in the study. The 
inclusion criteria were: women with a singleton pregnancy, at a gestational age ranging 24-30 
weeks, hospitalized for a first preterm labour episode (regular uterine contractions with cervical 
change documented by transvaginal ultrasound. Cervical change was defined as a length < 25 mm 
or a documented cervical length decrease of more than 10 mm within the previous four weeks of 
gestation. Exclusion criteria included: previous cervical surgery (conization, cervical cerclage), 
cervical length < 5 or > 35 mm, cervical dilatation > 2 cm, use of progestagens or other vaginal 
suppositories in the last 30 days.  
At hospital discharge, in women were randomized to receive either alpha-lipoic acid vaginal tablets 
400 mg, 1 tablet per day before sleep (Dav ®, LO. LI. Pharma, Rome, Italy) per 30 days or 
apparently similar tablets composed by the very same excipients as the active drug product except 
the active ingredient (placebo). 
During hospitalization, patients were treated according to the standard practice of our Institution, 
i.e, intravenous fluids, tocolytic therapy using Atosiban, steroid administration for respiratory 








2.2 Outcomes of the study 
The primary outcome of the study was the change in the profile of pro-inflammatory and anti-
inflammatory cytokines in cervical fluid. Monthly change of the cervical length (CL) was 
considered as a second outcome of the trial. Other outcome included the frequency of adverse 
events in patients allocated to placebo or ALA group. All outcomes were determined and the 
database was locked prior to the unsealing of the randomization code. 
 
2.3 Determination of pro- and anti-inflammatory cytokines 
All the samples for cytokine assays were obtained from the cervical fluid. Both sides of a Pre-
weighted Dacron swab were applied for 10 seconds. Swab was then weighed again, stirred in 1.5 ml 
saline solution, centrifuged and stored at -20°C, until assay. Cytokine concentrations were measured 
following the manufacturer’s instructions by the Ciraplex ® immunoassay kit (Aushon BioSytem 
Inc, Massachussets, US), a multiplex sandwich Enzyme-Linked ImmunoSorbent Assay (ELISA). 
Each well of the 96-well microplate is pre-spotted with protein specific antibodies. After the 
removal of excess detection antibody, streptavidin-horseradish peroxidases (SA-HRP) is added and 
the luminescent signal detected by Cirascan ® Imaging System (Aushon BioSytem Inc, 
Massachussets, US). Lower Limit of Quantification (LLOQ) and Upper Limit of Quantification 
(ULOQ) (pg/ml) with back-calculated concentration <20% and relative error <25% of the kit are: 
IL1α: 0.439;1,800, IL1β: 0.049; 200, IL4: 0.049; 200, IL6: 0.028; 114, IL8: 0.391;400, IL10: 0.049; 
200, TNFα: 0.391; 400. 
Changes in pro- and anti-inflammatory cytokines were considered as concentrations (pg/ml), mean 
of the percent changes (%) and the mean of the percent changes of the pro- (IL1, IL2, IL6, IL8, 








2.4 Determination of Cervical Length 
All the ultrasound evaluations of the CL were performed by the same operator in the Preterm Birth 
Clinic (LP) by  using a 25 Gold Mylab® (Esaote SpA®, Genoa, Italy) with an endo-vaginal probe 
model equipped for color Doppler imaging and power Doppler angiography (Model EC 1123). 
With the woman’s bladder emptied, the vaginal transducer was inserted into the anterior fornix of 
the vagina and positioned so that the endocervical canal is visualized. The ultrasound probe should 
be gradually withdrawn until the image is just visible to ensure there is not excessive pressure on 
the probe. A minimum of 3 CL measurements should be obtained by placing calipers at the internal 
and external os. The shortest and best measurement was recorded [25].  
 
2.5 Statistical analysis 
Data were analyzed by one of the authors (GG) who was blinded to the specific treatment of each 
group. Statistical analysis was performed by the statistical package StatView (version 5.01.98, SAS 
Institute Inc., Cary, NC). Within-group comparison was performed with the t-test for paired data 
and by the Wilcoxon signed-rank test for normal and non-normal data distribution, respectively. For 
all analyses, the null hypothesis was rejected at two-tailed p value < 0.05. Results are expressed as 










The flowchart of the study is reported in Figure 1. A total of 57 women were eligible according to 
the inclusion/exclusion criteria of the study and they were asked to participate. Of these, 40/57 
(70.2%) subjects accepted, signed the informed consent and were then randomized to the treatment 
groups (vaginal ALA vs. placebo) in a a ratio of 1:1 (20 subjects per group). No significant 
differences were found in subjects that reach final follow up visit [17/20 (85%) in vaginal ALA 
group, 15/20 (75%) in placebo  group, p=0.72]. 
The baseline features of the women included in the study are reported in Table 1 and comparable 
between groups, except that subjects in the vaginal ALA were more frequently included presenting 
both contractions and cervical changes at admission (p=0.03). 
 
3.1 Changes in the concentrations of cytokines in cervical fluid 
Baseline and after treatment values of cytokines are reported in Table 2. Baseline levels were not 
different between groups. 
The percent changes of pro- and anti-inflammatory cytokines were then considered. No 
significantly different changes were observed between groups as far as pro-inflammatory cytokines 
are concerned (vaginal ALA vs. placebo) (Figures 2a and 2c).  On the contrary, vaginal ALA 
induced a significant increase of IL4 in comparison to the placebo group (118.0±364.34% vs. 
29.9±103.5%, p=0.012) (Figure 2b). Once combined with IL10 changes, the increase of both anti-
inflammatory cytokines was significantly more pronunced in vaginal ALA group in comparison to 








3.2 Changes of cervical length 
Overall, cervical length remains similar in vaginal ALA group (from 23.1±6.6 to 20.8±7.9 mm), 
while it significantly decreased in the placebo group (from 20.4±6.5 to 13.8±7.5 mm, p=<0.001 vs. 
Baseline;  p=0.003 vs. vaginal ALA).  
The women were then divided according to cervical length at inclusion < 20 mm (n=11) (Figure 2a) 
or ≥ 20 mm (n=21) (Figure 2b). The general findings reported above were true for both subgroups 
(< 20 mm: p=0.014 vs. Vaginal ALA, p=0.009 vs. Baseline, ≥ 20 mm: p=0.05 vs. Vaginal ALA, 
p=0.002 vs. Baseline) (Figure 3a-b). 
 
3.3 Tolerability 
The only adverse effect reported in the vaginal ALA group was transient vaginal discomfort in 2/17 
(11.8%) of the subjects while none in the placebo group. The incidence of adverse effects was not 










4.1 Principal findings of the study 
In this pilot study, we have shown that vaginal ALA administration is associated with a specific 
anti-inflammatory effect at the cervical level in comparison to placebo, namely stimulating anti-
inflammatory cytokines. Vaginal ALA is more effective than placebo in limiting the monthly 
cervical shortening observed in women remaining undelivered after a preterm labor episode. Such 
effect is present both in women with a short cervix (< 20 mm) as well as in those with a cervical 
length above this cut-off.  However, whether this biological property of vaginal ALA could lower 
the risk of PTB (thus affecting neonatal morbidity/mortality) or not has to be evaluated in large 
randomized clinical trial. 
 
4.2 Interpretation 
The aetiology of PTB is complex and unfortunately still not understood. After an episode of 
threatened preterm labor with intact membranes, which is initially treated with tocolysis and 
corticosteroids for 48 h, women remain at risk for preterm delivery, as they deliver before 37 weeks 
at a rate ranging 38-75% [26-28]. 
Accumulated research indicate that infection and inflammation (most often subclinical) is an 
important underlying cause of PTB. In particular a recent systematic review has shown that IL6 and 
C-reactive protein in amniotic fluid, but not in plasma, are strongly associated with increased risk of 
spontaneous PTB among asymptomatic women, indicating that inflammation at the maternal–fetal 
interface rather than a systemic one, may play a major role in the etiology of such spontaneous 
PTB. These data are confirmed by the elevation of IL6 levels in the cervico-vaginal fluid which are 
also strongly associated with spontaneous PTB, suggesting that the local level presents the most 
important and subtle changes in women with PTB. However, there was insufficient evidence for the 
association between other inflammatory cytokines, like IL1, IL2, IL8 and TNF-α and spontaneous 









elucidated, but it is likely that inflammatory cytokines bring about parturition through increasing 
prostaglandin levels by affecting prostaglandins production, metabolism, or both.  
In this study, we focused on the activity of vaginal ALA at the cervical level. In ongoing 
experiments in female rats, addressed to verify ALA vaginal absorption, it was demonstrated by 
immunohistochemistry that the endometrial epithelial and stromal cells and the cervical squamous 
epithelium and muscular tissue were stained with intense amount of anti-ALA antibody, proving 
this route of administration very effective for ALA [30]. 
In our study the active treatment did not affect pro-inflammatory cytokines, including IL6. On the 
other hand, vaginal ALA stimulated the cervical secretion of IL4, an anti-inflammatory cytokine 
that induces differentiation of naive helper T cells to Th2 cells. It is well-known that a shift in the 
bias of overall maternal reactivity to the more conducive Th2 type, or at least a reduction in strong 
Th1 bias, may provide the best milieu to favor pregnancy [31].     
Moreover, polymorphisms of IL4 have been associated with spontaneous PTB [32] while its 
dysregulation has found to be correlated with Toll-Like receptor activity in cases of preterm 
neonates [33].  
Our findings are in agreement with the growing body of evidences suggesting the clinical use of LA 
when the abnormal regulation of the inflammatory response is recognized as an important 
component of the disease as in the case of diabetes, Alzheimer’s disease and multiple sclerosis [15]. 
In such conditions, LA exhibits anti-inflammatory properties by inhibiting IL6 and IL17 production 
and T cell proliferation and activation while possibly maintaining IL10 synthesis [15, 16, 30].  
On the other hand, CL is a marker of clinical value in the prediction of PTB, the shorter is the 
cervix, the higher is the risk of PTB [34, 35]. However, a progressive shortening of the cervix has 
been reported throughout physiological pregnancy. Namely, between 30 and 34 weeks the cervix 
shortens by 3 mm [36], the same change we observed in women receiving vaginal ALA. 
Considering that the cervix shorten the double in our women receiving placebo, the active 










4.3 Implications for further research 
The use of ALA represents a safe and well-tolerate treatment in many circumstances up to doses of 
2400 mg/day [37], also in pregnant women. We confirm tolerability in our small trial and 
demonstrated that vaginal ALA exerts a direct anti-inflammatory effect on the cervix, preventing its 
shortening after primary tocolysis. Such premise allows the planning of a clinical trial to explore the 
efficacy of  this treatment in the prevention of PTB. 
 
4.4 Strenghts and Limitations 
The major limitation of this study is the small sample size, thus it should be considered as a pilot 
study. Furthermore, the study was conducted in a single center and the results cannot be 
generalized. For all these reasons, results should be considered preliminary, although worthy to be 
explored in larger comparative investigations. 
 
4.5 Conclusion 
To the best of our knowledge, this is the first study investigating the effects of ALA administration 
through vaginal route after primary tocolysis. Such treatment induces significant changes in the 
cervical ILs pattern in undelivered women after a preterm labor episode, namely stimulating anti-
inflammatory cytokines. Moreover, the treatment is associated with a stabilization of the cervix, 
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8. Tables  
Table 1. Baseline features of the subjects randomized for the two different treatment groups 
(Placebo (n=20) and Vaginal ALA (n=20)). Values are expressed in mean±standard error (SE). 
 
 Placebo (n=20) Vaginal ALA (n=20) P 





Age (years) 30.8±1.5 28.5±1.5 0.305 
Nulliparous (%) 12/20 (60%) 13/20 (65%) 0.744 
Cervical lenght at inclusion 
(mm) 
20.4±1.9 23.1±1.5 0.270 
Need of tocolysis (%) 8/20 (40%) 10/20 (50%) 0.525 
Betamethasone need (%) 18/20 (90%) 19/20 (95%) 0.548 
Indication for admission 
- Contractions only (%) 
- Cervical change only (%) 
- Both contractions and 





















Table 2. Baseline and after treatment concentration (pg/ml) in the cervico-vaginal fluid of pro-
inflammatory (IL1, IL2, IL6, IL8, TNFα) and anti-inflammatory (IL4, IL10) cytokines of the 
subjects randomized for the two different treatment groups (Placebo (n=15) and Vaginal ALA 
(n=17). Values are expressed in median (inter-quartile ranges). * p< 0.05 
Cytokines  Baseline After treatment 
Pro-inflammatory   
IL1(pg/ml) Vaginal ALA (n=17) 192.12 (56.18; 266.78) 297.18 (113.85;386.75) 
Placebo (n=15) 343.43 (87.55;567.65) 590.31 (246.48;713.54) 
IL2 (pg/ml) Vaginal ALA (n=17) 0.70 (0.31;1.35) 0.48 (0.18;1.93) 
Placebo (n=15) 1.11 (0.83;1.47) 0.73 (0.17;1.78) 
IL6 (pg/ml) Vaginal ALA (n=17) 33.45 (1.04;79.86) 84.20 (0.27;166.77) 
Placebo (n=15) 6.25 (1.71;14.50) 3.00 (2.50;25.50) 
IL8 (pg/ml) Vaginal ALA (n=17) 146.50 (0.35;1,586.00) 652.70 
(135.70;1,470.00) 
Placebo (n=15) 674.20 
(394.1;1,455.00) 
283.00 (89.35;1,410.00) 
TNFα (pg/ml) Vaginal ALA (n=17) 0.27 (0.10;1.39) 0.16 (0.08;1.89) 
Placebo (n=15) 0.40 (0.21;0.67) 1.35 (0.41;3.22) 
Anti-inflammatory   
IL4 (pg/ml) Vaginal ALA (n=17) 0.03 (0.01;0.14) 0.09 (0.03;0.21)* 
Placebo (n=15) 0.07 (0.03;0.10) 0.05 (0.02;0.07) 
IL10 (pg/ml) Vaginal ALA (n=17) 0.16 (0.01;0.35) 0.59 (0.04;3.44) 









9. Legends for Figures 
Figure 1. Flow-chart of the study. 
Figure 2. Percent changes of cytokines concentrations in the cervical secretion after 30 days of 
treatment with vaginal ALA or placebo. Changes of pro-inflammatory cytokines (IL1, 2, 6, 8 and 
TNFα) are reported separately (Figure 2a) from those of anti-inflammatory cytokines (IL4 and 
IL10) (Figure 2b). The bottom panel reports them (pro- and anti-inflammatory) combined (Figure 
2c). Bars represent scattergram with medians. Continuous line: ALA group. Dashed line: Placebo 
Group. 
* p<0.05 vs. Vaginal ALA 
Figure 3. Changes of CL after 30 days of treatment with vaginal ALA or placebo in subjects with a 
cervical length at inclusion <20 mm (n=11) (Figure 3a) or ≥20 mm (n=21) (Figure 3b). Bars 
represent means±standard error (SE). 
* p<0.05 vs. Vaginal ALA 
** p<0.01 vs. Baseline  
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